Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients
Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients
复制标题
DOI：
10.1007/s10456-006-9033-1
复制
发表时间：
2006-01-01
期刊：
影响因子：
9.8
通讯作者：
Jiang, Wen G.
中科院分区：
文献类型：
--
作者：
Parr, Christian;Gan, Chun H.;Jiang, Wen G.
血管内皮生长抑制因子（VEGI）是一种新的抗血管生成的细胞因子，属于肿瘤坏死因子（TNF）超家族。关于VEGI在癌症中的意义知之甚少。我们的研究分析了VEGI表达与乳腺癌患者临床参数的关系。在一组24个人正常和癌细胞系和一组151个乳腺组织样本（n = 33个正常乳腺组织; n = 118个乳腺癌组织）中，对VEGI表达谱进行了定性（RT-PCR）、定量（实时定量PCR）和免疫组织化学（IHC）评估，中位随访时间为6年。死于乳腺癌或局部复发的患者表达的VEGI水平显著低于无疾病患者的升高水平。高水平的VEGI与患者生存机会增加相关。重要的是，表达VEGI水平降低的乳腺肿瘤患者的预后比表达高水平VEGI的患者差。然而，VEGI表达与肿瘤分级、TNM分类或淋巴结受累之间没有显著相关性。总之，VEGI在人乳腺癌组织中异常表达。VEGI显示预后相关性，因为与具有良好预后的那些患者相比，具有总体不良预后的乳腺癌患者表达显著较低水平的VEGI。
Vascular endothelial growth inhibitor (VEGI) is a novel anti-angiogenic cytokine that belongs to the tumour necrosis factor (TNF) superfamily. Very little is known about the significance of VEGI in cancer. Our study analysed VEGI expression in relation to breast cancer patient clinical parameters. The VEGI expression profile was assessed qualitatively (RT-PCR), quantitatively (real-time Quantitative-PCR), and immuno-histochemically (IHC), in a panel of 24 human normal and cancer cell lines and in a cohort of 151 mammary tissue samples (n = 33 normal breast tissue; n = 118 breast cancer tissue) with a 6-year median follow-up. Patients who had died of breast cancer or had local recurrence of the disease expressed significantly lower levels of VEGI in comparison to the elevated levels in the disease free patients. High levels of VEGI were associated with an increased chance of patient survival. Importantly, patients with breast tumours expressing reduced levels of VEGI had a poorer prognosis than those patients expressing high levels of VEGI. However, no significant correlations were observed between VEGI expression and tumour grade, TNM classification, or nodal involvement. In conclusion, VEGI is aberrantly expressed in human breast cancer tissues. VEGI displays prognostic relevance as breast cancer patients with an overall poor prognosis express significantly lower levels of VEGI compared to those with a favourable prognosis.